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Background: Serum total cholesterol and its fractions are inversely associated with intracerebral hem-
orrhages (ICH) and their potential subclinical precursor, cerebral microbleeds. To ascertain whether there
is a genetic basis for this inverse association, we studied established genetic loci for serum total, LDL, and
HDL cholesterol, and triglycerides in their association with ICH and microbleeds.
Methods: Data on 161 genetic variants for serum lipids was collected in 9011 stroke-free participants
(mean age 65.8, SD 10.2; 57.9% women) of the population-based Rotterdam Study. Participants were
followed from baseline (1997e2005) up to 2013 for the occurrence of ICH. A subset of 4179 participants
underwent brain MRI for microbleed assessment between 2005 and 2011. We computed genetic risk
scores (GRS) for the joint effect of lipid variants. Cox proportional hazards and logistic regression models
were used to investigate the association of GRS of lipid fractions with ICH and microbleeds.
Results: After a mean follow-up of 8.7 (SD 4.1) years, 67 (0.7%) participants suffered an ICH. Microbleed
prevalence was 19.6%. Higher genetic load for high serum total and LDL cholesterol was associated with
an increased risk of ICH. Higher genetic load for high serum LDL cholesterol was borderline associated
with a higher prevalence of multiple lobar microbleeds.
Conclusions: Genetic susceptibility for high serum total and LDL cholesterol is positively associated with
incident ICH and borderline associated with multiple lobar microbleeds. We did not ﬁnd a genetic basis
for the previously reported inverse association between serum lipid levels and ICH.
© 2016 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY
license (http://creativecommons.org/licenses/by/4.0/).1. Introduction
Hypercholesterolemia is an established modiﬁable risk factor
for ischemic cardiovascular disease, including ischemic stroke.
Paradoxically, high serum total cholesterol has been associated
inversely with clinical intracerebral hemorrhages (ICH) [1e4] and
their potential subclinical precursor, cerebral microbleeds [5e8].
Profound insight into this seemingly contradictory association is
essential given the growing concern of adverse ICH events in per-
sons vigorously treated with lipid-lowering medication [9e11].
To date, studies have focused solely on serum lipid levels to
investigate the inverse associationwith ICH. Some studies reportededical Center, Na28-18, Post-
Vernooij).
r Ireland Ltd. This is an open accesthat low total cholesterol drove this association [1,2,4], whilst
others pointed towards a speciﬁc lipid fraction [3,5,6]. Results from
these studies are, however, limited by the fact that serum lipid
levels were measured only once, and associations may partly be
explained by residual confounding due to unmeasured de-
terminants, such as diet. No study reported on a potential genetic
basis for the inverse association of serum lipids with ICH. Studying
genes that inﬂuence serum lipid levels may provide more robust,
unconfounded associations, as genes should not be susceptible to
changes in lifestyle or environment.
We investigated 161 known genetic loci for serum total, HDL,
and LDL cholesterol, and triglycerides and studied their associa-
tions with risk of ICH and with presence of their potential sub-
clinical precursor, cerebral microbleeds.s article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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2.1. Study population
This study was conducted within the Rotterdam Study, a pro-
spective population-based cohort study aimed at investigating
determinants and consequences of chronic diseases in an aging
population [12]. In 1990, 7983 persons (78% of invitees) were
included in the initial study wave (RS-I). In 1999, the cohort was
expanded by 3011 participants (67% of invitees) (RS-II). The cohort
expanded a second time in 2006 with 3932 participants (65% of
invitees) (RS-III). The total of 14,926 participants enrolled, were
invited to undergo home interviews and various physical and lab-
oratory examination at the research center every 4 years. Geno-
typing was done in 1997 (RS-I), 1999 (RS-II), and 2006 (RS-III). Of
the 14,926 participants, 9011 were genotyped and stroke-free at
baseline (Fig. 1). From 2005 onwards, brain MRI, including micro-
bleeds assessment, was performed in those without MRI contra-
indications (pacemakers, claustrophobia) [13,14]. Of the 9011
stroke-free participants who were included at baseline, 4179 un-
derwent brain MRI scanning between 2005 and 2011.
2.2. Genotyping
Participants were genotyped using Illumina HumanHap 550
Duo BeadChip or the Illumina Inﬁnium II HumanHap 610 Quad
Arrays. Genotyping was done at the Human Genotyping Facility
Genetic Laboratory department of Internal Medicine, Erasmus MC,
Rotterdam, the Netherlands [14]. Variant-speciﬁc quality controls
included ﬁlters for call rate (>98%), minor allele frequency (>0.1%),Fig. 1. Schematic overview oHardyeWeinberg equilibrium (p-values>10e6), and differential
missingness by outcome or genotype (mishap test in PLINK, http://
pngu.mgh.harvard.edu/purcell/plink/). Markov Chain Haplotyping
(MaCH) package (http://www.sph.umich.edu/csg/abecasis/MACH,
version 1.0.15 or 1.0.16 software) was used for imputation to the
1000 Genomes Phase I Version 3 reference panel (all populations).
For each imputed variant, quality of imputation was estimated as
the ratio of the empirically observed dosage variance to the ex-
pected binomial dosage variance. For this study, we extracted data
on 161 variants, 73 which have been related to serum concentra-
tions of total cholesterol, 56 to LDL, 71 to HDL, and 39 to tri-
glycerides (Supplementary Table 1) [15]. Imputation quality (R2) for
the serum lipid variants was >0.60 (mean ¼ 0.96).
2.3. Assessment of stroke
Stroke was deﬁned as a syndrome of rapidly developing clinical
signs of focal or global disturbance of cerebral function, with
symptoms lasting 24 h or leading to death, with no apparent cause
other than of vascular origin [16]. A history of stroke was assessed
in all participants upon study entry using home interviews and was
conﬁrmed by reviewing medical records. Participants were subse-
quently followed for stroke occurrence through automated linkage
of general practitioners’ medical records with the study database.
Medical records from nursing homes and from general practi-
tioners of participants who moved out of the study area were
checked on a regular basis. Research physicians reviewed all po-
tential strokes using hospital discharge letters and information
from general practitioners. An experienced vascular neurologist
veriﬁed the stroke diagnoses [17]. Computed tomography reportsf the study population.
S. Akoudad et al. / Atherosclerosis 246 (2016) 287e292 289were used to distinguish intracerebral hemorrhages from ischemic
strokes. Strokes were classiﬁed as unspeciﬁed if neuroimaging was
absent. Follow-up was complete until January 1st 2013 accounting
for 77,991 (98.2% of potential) person-years. In total, 7.5% of the
person-years follow-up was collected via records of nursing homes
and records of general practitioners of patients who moved out of
the study area.
2.4. Brain MRI and microbleed assessment
A multi-sequence MRI protocol was used on a 1.5-Tesla MRI
scanner (GE Healthcare, Milwaukee, WI) [13]. Cortical infarcts were
deﬁned as focal lesions affecting the cortical gray matter on FLAIR,
T1-weighted, and T2-weighted sequences. Microbleeds were
detected using a custom-made accelerated 3-dimensional T2*-
weighted gradient-recalled echo sequence (repetition
time ¼ 45 ms, echo time ¼ 31, matrix size ¼ 320  244, ﬂip
angle ¼ 13, ﬁeld-of-view ¼ 25  17.5 cm2, parallel imaging accel-
eration factor¼ 2, 3D acquisitionwith 96 slices encodedwith a slice
thickness of 1.6 mm zero padded to 192 slices of 0.8 mm, acquisi-
tion time 5 min 55 sec) [18]. Microbleeds were deﬁned as small,
round areas of signal loss on T2*-weighted images and their pres-
ence, number, and location were rated by trained research-
physicians [18].
2.5. Covariates
Serum total cholesterol, HDL cholesterol, and triglyceride levels
were determined using an automated enzymatic procedure (Hita-
chi analyzer, Roche Diagnostics, Washington DC). LDL cholesterol
was calculated using the Friedwald formula (LDL cholesterol¼ total
cholesterol e HDL cholesterol e triglycerides/2.17), in those with
triglyceride levels 4.51 mmol/L [19]. If serum lipids levels were
not assessed at time of MRI, serum lipid levels of a preceding visit
were used (Fig. 1). Records on lipid-lowering medication use (ATC-
code C10), blood-pressure lowering medication (ATC-code C02-03,
c07-09), and antithrombotic medication (ATC-code B01AA, B01AB,
B01AC, B01AX) were retrieved from local pharmacies serving the
study area. Blood pressures measurements were averaged over 2
readings measured within a single center visit using a random-zero
sphygmomanometer. Smoking habits were deﬁned as ever versus
never smoking. Diabetes mellitus was deﬁned as having fasting
glucose levels of 7.0 mmol/L or the use of glucose-lowering
medication. Body-mass-index was calculated as weight (in kilo-
grams) divided by height (in meters) squared.
2.6. Statistical analysis
We computed weighted genetic risk scores (GRS) for total, LDL,
and HDL cholesterol, and triglycerides by summing the number of
serum lipid fraction effect alleles and weighting them by the re-
ported effect estimate of each lipid variant (73 variants for total
cholesterol, 56 variants for LDL cholesterol, 71 variants for HDL
cholesterol, and 39 variants for triglycerides using results from the
GWAS on serum lipids) [15]. Note that most variants were pleio-
tropic and thus there was overlap across the risk scores.
Cox proportional hazards models were used to compute the
estimated hazard ratios (HR) and 95% conﬁdence intervals (CI) for
the association of serum lipid fractions and GRS of lipid fractions
with incident ICH. Logistic regressionmodels were used to estimate
odds ratios (OR) and 95% CI for the association of serum lipid
fractions and GRS of lipid fractions with presence of cerebral
microbleeds on MRI. Microbleeds were categorized by their loca-
tion and count (single andmultiple strictly lobar and deep or mixed
microbleeds versus nomicrobleeds) [18]. We ﬁtted 3models for themain analyses, adjusting for age and sex in the ﬁrst model, addi-
tionally for serum lipid levels and lipid-lowering medication in the
second model, and cardiovascular risk factors (blood pressures,
smoking habits, diabetes mellitus, body-mass-index, blood
pressure-lowering and antithrombotic medication use) in the third
model. Variance inﬂation factor was calculated to detect possible
multicollinearity in the models described above. For microbleeds,
analyses were repeated after excluding participants with cortical
infarcts on MRI (N ¼ 151). Also, we repeated the analysis for ICH
and cerebral microbleeds after excluding APOE alleles from the GRS.
Missing cardiovascular covariate data (7%) were imputed
based on sex, age, and cardiovascular risk factors using logistic
regression models. Analyses were done using IBM SPSS statistic for
Windows, Version 21.0 (IBM Corp., Armonk, NY), using an alpha-
value of 0.05.
3. Results
Baseline characteristics of the study population are presented in
Table 1. During a mean follow-up of 8.7 years (SD 4.1), 67 (0.7%)
participants suffered an ICH. The prevalence of lobar microbleeds
and the prevalence of deep or infratentorial microbleeds in those
who underwent MRI (n ¼ 4179) was respectively 12.9% and 6.7%.
GRS of total, LDL, and HDL cholesterol and triglycerides were
strongly associated with their corresponding serum lipid fraction
(respectively P ¼ 6.2  1083 for total cholesterol, P ¼ 5.0  1071
for LDL cholesterol, P ¼ 2.4  10102 for HDL cholesterol, and
P ¼ 7.0  1096 for triglycerides) (Supplementary Table 2). Asso-
ciations of fasting serum lipid levels with ICH and microbleeds are
shown in Supplementary Tables 3 and 4 Although not signiﬁcant,
serum triglycerides associated inversely with ICH risk and micro-
bleed presence. Additionally, serum HDL cholesterol was inversely
related to lobarmicrobleeds, whereas LDL cholesterol was inversely
associated with deep or infratentorial microbleeds.
Table 2 shows the association of GRS of serum lipid fractions
with incident ICH. Higher GRS of total cholesterol was associated
with an increased risk of ICH, even after adjusting for serum total
cholesterol, lipid-lowering medication, and cardiovascular risk
factors (Model 3 HR 1.32, 95% CI 1.03e1.70, P value 0.031). Per
standard deviation increase in the GRS of LDL cholesterol the risk of
ICH increased signiﬁcantly (Model 1, age and sex adjusted HR 1.32,
95% CI 1.04e1.68, P value 0.024). No associations were found for
GRS of HDL cholesterol and triglycerides with ICH (Model 1-3). GRS
of LDL was associated with ICH even after excluding APOE alleles
from the risk score (age and sex adjusted HR: 1.27, 95% CI 1.00e1.62,
P value 0.053, HR additionally adjusted for serum LDL levels and
lipid-loweringmedication: 1.32, 95% CI 1.03e1.70, P value 0.029, HR
additionally adjusted for cardiovascular risk factors: 1.32, 95% CI
1.03e1.70, P value 0.028).
The association between GRS of lipid fractions and cerebral
microbleeds is presented in Table 3. Higher GRS of LDL cholesterol
was borderline associated with a higher prevalence of multiple
lobar microbleeds (OR 1.17, 95% CI 1.00e1.38, P value 0.054). GRS of
lipid fractions were not associated with deep or infratentorial
microbleeds. Additional adjustments for serum lipid fractions,
lipid-lowering medication, and cardiovascular risk factors did not
alter the results (data not shown). Overall, there was no indication
of multicollinearity as the variance inﬂation factor was consistently
below 2. The association between GRS of LDL and multiple lobar
microbleeds disappeared after excluding APOE alleles from the GRS
(age and sex adjusted OR 1.03, 95% CI 0.88e1.21, P value 0.720).
4. Discussion
In this population-based study, we found that genetic
Table 1
Baseline characteristics of the study population.
Complete cohort N ¼ 9011 Set with MRI N ¼ 4179 Pa
Age, years 65.8 (10.2) 64.2 (11.0) <0.001
Women 5214 (57.9) 2286 (54.7) 0.001
Serum total cholesterol, mmol/L 5.7 (1.0) 5.6 (1.1) <0.001
Serum LDL cholesterol, mmol/L 3.7 (0.9) 3.5 (0.9) <0.001
Serum HDL cholesterol, mmol/L 1.4 (0.4) 1.4 (0.4) <0.001
Serum triglycerides, mmol/L* 1.4 (1.0e1.8) 1.3 (1.0e1.8) 0.836
Use of lipid-lowering medication 1346 (14.9) 1020 (24.4) <0.001
Systolic blood pressure, mmHg 140.1 (20.8) 139.2 (21.3) 0.053
Diastolic blood pressure, mmHg 78.5 (11.3) 82.3 (10.9) 0.008
Use of blood pressure-lowering medication 5956 (66.1) 1957 (46.8) <0.001
Use of antithrombotic medication 4350 (48.5) 1229 (29.4) <0.001
Smoking 6337 (70.3) 2944 (70.4) 0.886
Diabetes mellitus 906 (10.1) 352 (8.4) 0.003
Body mass index, kg/m2 27.2 (4.1) 27.4 (4.1) 0.928
Values represent mean (standard deviation) or *median [interquartile range] for continuous variables, and number (percentage) for categorical variables.
a P value for the difference in baseline characteristics in the complete cohort and cohort with MRI.
Table 2
Genetic risk scores of lipid fractions and the risk of intracerebral hemorrhage.
Intracerebral hemorrhages
Hazard ratios (95% conﬁdence interval)
Genetic risk scores Events/number at risk Model 1 P Model 2 P Model 3 P
Total cholesterol 67/9011 1.24 (0.98e1.58) 0.073 1.32 (1.03e1.69) 0.029 1.32 (1.03e1.70) 0.031
LDL cholesterol 67/9011 1.32 (1.04e1.68) 0.024 1.38 (1.08e1.77) 0.011 1.40 (1.09e1.79) 0.009
HDL cholesterol 67/9011 1.04 (0.82e1.32) 0.771 1.01 (0.79e1.30) 0.909 1.03 (0.80e1.32) 0.807
Triglycerides 67/9011 0.89 (0.70e1.13) 0.340 0.94 (0.73e1.20) 0.623 0.94 (0.73e1.20) 0.602
Values represent adjusted hazard ratios for intracerebral hemorrhages in relation to genetic risk scores of lipid fractions (increase per Z-scores).
Model 1: adjusted for age and sex.
Model 2: adjusted for age, sex, corresponding lipid fraction (serum total cholesterol for total cholesterol risk score, LDL for LDL risk score, serum HDL for HDL risk score, serum
triglyceride for triglyceride risk score), and lipid-lowering medication.
Model 3: as model 2, additionally adjusted for blood pressures, ever smoking, diabetes mellitus, body-mass-index, blood-pressure lowering medication, and antithrombotic
medication use.
Abbreviations: LDL ¼ low-density lipoprotein, HDL ¼ high-density lipoprotein.
Table 3
Genetic risk scores of lipid fractions and microbleeds by location and count.
Microbleeds
Odds ratios (95% conﬁdence interval)
Events/total
population
Yes vs No P Events/total
population
Single vs No P Events/total
population
Multiple vs No P
Genetic risk scores Strictly lobar microbleeds
Total cholesterol 539/3900 1.01 (0.92e1.11) 0.832 379/3740 0.96 (0.86e1.07) 0.463 160/3521 1.14 (0.97e1.34) 0.109
LDL cholesterol 539/3900 1.07 (0.97e1.17) 0.179 379/3740 1.02 (0.92e1.14) 0.667 160/3521 1.17 (1.00e1.38) 0.054
HDL cholesterol 539/3900 1.01 (0.92e1.11) 0.771 379/3740 1.00 (0.98e1.11) 0.927 160/3521 1.06 (0.90e1.25) 0.465
Triglycerides 539/3900 0.93 (0.85e1.02) 0.133 379/3740 0.91 (0.82e1.02) 0.098 160/3521 0.98 (0.84e1.15) 0.796
Deep or infratentorial microbleeds
Total cholesterol 279/3640 1.01 (0.89e1.15) 0.869 107/3468 0.92 (0.75e1.12) 0.387 172/3533 1.08 (0.92e1.27) 0.371
LDL cholesterol 279/3640 1.00 (0.88e1.14) 0.969 107/3468 0.87 (0.71e1.06) 0.869 172/3533 1.10 (0.94e1.30) 0.238
HDL cholesterol 279/3640 1.04 (0.92e1.18) 0.549 107/3468 1.15 (0.95e1.39) 0.153 172/3533 0.97 (0.83e1.14) 0.694
Triglycerides 279/3640 0.93 (0.82e1.06) 0.272 107/3468 0.88 (0.72e1.06) 0.179 172/3533 0.97 (0.83e1.14) 0.726
Values represent age and sex adjusted odd ratios for categories of single and multiple microbleeds in relation to genetic risk scores for lipid fractions (increase per Z-scores).
Abbreviations: LDL ¼ low-density lipoprotein, HDL ¼ high-density lipoprotein.
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increased risk of ICH. In addition, higher GRS of LDL cholesterol
associated with a higher prevalence of multiple lobar microbleeds.
Associations remained unchanged after adjusting for serum lipid
concentrations, lipid-lowering medication, and cardiovascular risk.
Strengths of this study include the prospective population-
based design aiding generalizability, the large number of partici-
pants, which enhances statistical power, and the virtually complete
follow-up for ICH. Our ﬁndings have to be interpreted in light of
some limitations. First, strokes were classiﬁed as unspeciﬁed in theabsence of neuroimaging, thus some ICH cases may have been
misclassiﬁed. In addition, the number of ICH cases in our study was
small. Second, our study population comprised mostly persons of
European ancestry. Third, the RS-I and RS-II subcohorts used in this
study were part of the GWAS that identiﬁed the serum lipid genes,
and accounted for 7.3% of the entire discovery cohort. Fourth, for
850 participants we adjusted for serum lipid levels that were
measured in visits preceding brain MRI (Fig. 1). Yet, it should be
noted that as we cannot date microbleed occurrence on baseline
MRI scans, measuring lipid concentrations at the same time as
S. Akoudad et al. / Atherosclerosis 246 (2016) 287e292 291microbleed assessment does not necessarily lead to better adjust-
ments of potential confounding.
In our study, a higher genetic load for high serum LDL was
associated with an increased risk of ICH. Although our ﬁndings are
in line with another observational study that investigated serum
lipid levels and incident ICH [20], we were unable to corroborate
ﬁndings from the majority of studies reporting inverse associations
of total cholesterol [1e3,5,21,22], LDL cholesterol [2,3,5,21,22], and
HDL cholesterol [3,5,22] with ICH. This includes ﬁndings from a
meta-analysis of 23 prospective cohort and nested prospective
case-control studies accounting for 7960 ICH cases (5.6% of the total
meta-analysis study population) [3], which reported that lower
serum total and LDL cholesterol related to an increased risk of ICH.
No associations were found for HDL cholesterol or triglycerides. The
mechanism by which low serum lipids would inﬂuence the path-
ogenesis of ICH is unclear but it has been suggested that low lipid
levels negatively affect the preservation of vessel wall integrity
[23e25]. Low total cholesterol levels may cause smooth muscle
cells to degenerate, which weakens the endothelial layer of intra-
cerebral vessel walls. This causes vascular hyperpermeability and
precipitates the extravasation of erythrocytes [23e25]. On the
other hand, low total cholesterol may also be a secondary phe-
nomenon in ICH patients with hypertension and excessive alcohol
usage [4].
Our study provides no evidence for a genetic basis for the in-
verse association of lipid fractions and incident ICH. The disparity
between our ﬁndings and that of previous studies may partly be
explained by the fact that serum lipid fractions were typically
measured only once, whereas lipid genes provide a more reliable
lifetime exposure risk to elevated serum lipids levels. Also, in-
dividuals at highest risk of ICH may have had more aggressive risk
factor management (i.e., lipid-lowering medication use, low-fat
diet, increased physical activity). Insufﬁcient adjustment for these
factors in data analysis may have led to confounding in studies
investigating serum lipid levels and ICH. Additionally, residual
confounding due to unmeasured factors may also have inﬂuenced
their ﬁndings to some extent. Our results provide more robust as-
sociations as genes are not susceptible to changes in lifestyle or
environment. Finally, most studies investigating serum lipid levels
did not control for competing risk of ischemic stroke, coronary
heart disease or mortality. Thus, in these studies, less people with
elevated serum lipid levels may have been at risk for ICH due to
prior occurrence of other cardiovascular events or death.
The associations between GRS of lipid fraction and multiple
strictly lobar microbleeds followed the same trend as that of
intracerebral hemorrhages, suggesting that these types of intra-
cranial bleedingsmay share commonpathophysiological pathways.
If we presume multiple lobar microbleeds to be precursors of
ICH [26,27], our ﬁndings suggest that high genetic load for high
serum LDL cholesterol facilitates the progression of cerebral vas-
culopathy. This progression may particularly be mediated by the
presence of APOE risk alleles, as we only found an association be-
tween GRS of LDL andmultiple lobar microbleeds oncewe included
APOE alleles in the GRS. After excluding APOE alleles, we found no
reason to assume that genetic susceptibility for high serum lipids
differs across cerebral vasculopathies, as results were similar for
microbleeds in regions typically affected by cerebral amyloid
angiopathy (lobar regions) and for microbleeds in regions charac-
teristically affected by hypertensive arteriopathy (deep or infra-
tentorial regions).
In conclusion, in a large population-based cohort we found that
higher genetic load for high serum total and LDL cholesterol in-
creases the risk of ICH and was borderline signiﬁcantly associated
with a higher prevalence of multiple lobar cerebral microbleeds.
We found no genetic support for the paradoxical inverseassociation of serum lipid fractions with ICH and microbleeds as
reported previously by our and other observational studies. Our
current ﬁndings suggest that high LDL cholesterol is amongst the
modiﬁable risk factors for ICH. However, since these ﬁndings are in
contrast with the majority of the previous published studies, these
observations could be considered hypothetical and need conﬁr-
mation in studies with larger sample size and repeated LDL
cholesterol measurements.
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